Vir Biotechnology misses Q3 revenue estimates

Vir Biotechnology

05/11/2025 21:24

Overview

Vir Biotechnology Q3 revenue missed analyst expectations, declining significantly year-over-year

Net loss for Q3 decreased to $163.1 mln from $213.7 mln year-over-year

Company maintains strong cash position with $810.7 mln, funding operations into mid-2027

Outlook

Company expects cash reserves to fund operations into mid-2027

Topline data for ECLIPSE trials expected in Q1 2027

Result Drivers

R&D expenses for the third quarter of 2025 were $151.5 million, compared to $195.2 million for the same period in 2024

ONCOLOGY EXPANSION - First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs for prostate cancer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$200,000
$1.98 mln (7 Analysts)
Q3 EPS
-$1.17
Q3 Net Income
-$163.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.00, about 65% above its November 4 closing price of $5.25

Press Release: ID:nBwYcK9Qa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)